Register entry
- Registered sites
- 0
- Active NDC listings
- 1
- Live patents
- 6
- Exclusivities
- 1
- Countries
- 0
Exclusivity
Patents and exclusivities
6| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 10881747 | CYTALUXpafolacianine sodium | substance, product | Aug 2033 |
| 9333270 | CYTALUXpafolacianine sodium | substance, product | Aug 2033 |
| 9341629 | CYTALUXpafolacianine sodium | substance, product | Aug 2033 |
| 9789208 | CYTALUXpafolacianine sodium | substance, product | Aug 2033 |
| 9254341 | CYTALUXpafolacianine sodium | substance, product | Oct 2033 |
| 9061057 | CYTALUXpafolacianine sodium | substance, product | Nov 2035 |
| Product | Exclusivity | Until |
|---|---|---|
| CYTALUXPAFOLACIANINE SODIUM | ODE-390 Orphan drug | Nov 2028 |
Catalogue
Marketed products
1| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| Cytalux | Pafolacianine injection | injection, intravenous | 81052-138NDA |
Enquiry
Common questions
- Is On Target Laboratories, Inc. FDA approved?
- On Target Laboratories, Inc. holds no registered establishment of its own; 1 drug product is listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does On Target Laboratories, Inc. make?
- 1 product is listed under On Target Laboratories, Inc. in the openFDA NDC Directory, most often as injection. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.